Immuno-Oncology

Dr. Sundar Jagannath discusses the benefits in progression-free survival and quality of life from newly-approved therapies for patients with multiple myeloma.

Immunotherapy expert, Dr. Jeffrey Weber, talks about the importance of early intervention for immune-related adverse events.

Dr. Jeffrey Weber describes the organ-specific side effects that can occur in a patient on checkpoint inhibitors.

Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.

Immunotherapy agent atezolizumab approved by FDA for treatment of NSCLC.

Dr. Omid Hamid discusses some toxicities that come from combination immunotherapies

The treatment of TNBC is rapidly evolving, with immotherapies, AR-targeted agents and targeted therapies.

Yvonne Saenger, MD, from Columbia University, gives a rundown of the immunotherapy options for treating melanoma.

Immunotherapy is changing the cancer treatment game as therapies continue to be approved for more and more tumor types. This creates more responsibilities for oncology nurses.

An oncology nurse's overview of immunotherapy.

Cancer immunotherapies continue to show promising clinical outcomes, notably long-lasting remission, for an increasing number of malignancies.

Some immune-related adverse events (irAEs) can be life threatening. Researchers in Spain recently published a review of the most common endocrine irAEs and their management strategies.

The immunotherapy pembrolizumab (Keytruda) has been granted an accelerated approval from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progresses after platinum-based chemotherapy.

Our immune system’s successful detection and destruction of abnormal cells is the hallmark of our body’s ability to either stop a malignancy from occurring or halt it once it has begun.

Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.

Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.

Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses nurses’ roles in treating patients receiving immunotherapy, especially combination checkpoint blockades, which are typically associated with higher risks of adverse events.

​Sumanta K. Pal, MD, City of Hope Cancer Center, discusses the role that nurses will play in the shifting paradigm of cancer treatment.

​Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses the side effects of immunotherapy on patients with non-small cell lung cancer.

Encouraging findings for PD-1 inhibitor–based immunotherapies for the treatment of patients with metastatic head and neck cancer are emerging from clinical studies.

Robert Andtbacka, MD, from University of Utah School of Medicine, discusses the management of side effects from T-VEC.

While immunotherapies continue to gain traction across multiple tumor types, including malignancies of the central nervous system, these agents are also associated with unique adverse events.

The FDA has approved the first-in-class oncolytic viral therapy Imlygic (T-VEC; talimogene laherparepvec) for the local treatment of unresectable lesions of the skin and lymph nodes in patients with melanoma that recurred after initial surgery.

Suresh S. Ramalingam, MD, discusses important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.

A phase III trial evaluating the efficacy of nivolumab (Opdivo) for the treatment of advanced renal cell carcinoma has been stopped early after the immunotherapy agent demonstrated a survival advantage over the comparator drug, everolimus (Afinitor), in the CheckMate-025 trial.